Zepbound Cancer Risk Signal Review: What the Clinical Evidence Actually Shows

Why a Cancer Risk Review Matters for Tirzepatide

Tirzepatide is a dual GIP and GLP-1 receptor agonist approved by the FDA in May 2022 for type 2 diabetes (Mounjaro) and in November 2023 for chronic weight management (Zepbound). In SURMOUNT-1 (N=2,539), the 15 mg dose produced a mean body-weight loss of 20.9% at 72 weeks versus 3.1% with placebo, making it the most effective approved pharmacotherapy for obesity to date [1].

That efficacy comes alongside a class-wide safety profile that includes a prominent FDA boxed warning. Clinicians and patients reviewing the label encounter the phrase "thyroid C-cell tumors" on the first page. Understanding exactly what that signal means, where it comes from, and what it does not mean requires separating rodent pharmacology from human oncology.

The Regulatory History in Brief

The boxed warning for thyroid C-cell tumors applies to all approved GLP-1 receptor agonists, including semaglutide (Ozempic/Wegovy), liraglutide (Victoza/Saxenda), dulaglutide (Trulicity), and exenatide (Byetta/Bydureon). Tirzepatide received the same warning during its NDA review because the preclinical package showed dose-dependent C-cell hyperplasia and tumors in Sprague-Dawley rats [2].

What "Signal" Actually Means

A safety signal is not a confirmed risk. The FDA defines a signal as "information that arises from one or more sources suggesting a new potentially causal association, or a new aspect of a known association, between an intervention and an event." The thyroid finding in tirzepatide's preclinical program met that threshold for labeling purposes without meeting the threshold for confirmed human carcinogenicity.

Rodent Thyroid Findings: The Source of the Boxed Warning

The preclinical data that drove the boxed warning come from two-year carcinogenicity studies in Sprague-Dawley rats. These animals are known to have high GLP-1 receptor (GLP-1R) expression on thyroid C-cells and are considered a sensitive model for C-cell neoplasia. Tirzepatide produced C-cell hyperplasia and adenomas at all dose levels tested, with malignant C-cell carcinomas at higher exposures [2].

Why Rodent Data Do Not Directly Predict Human Risk

Several biological differences limit the translational relevance of these findings:

• GLP-1R expression density. Human thyroid C-cells express GLP-1R at substantially lower levels than rat C-cells. A 2011 analysis by Waser et al. Using receptor autoradiography found that GLP-1R density on human C-cells was low to undetectable in most samples, while rat C-cells showed high receptor density [3].
• Species-specific C-cell proliferation. Sprague-Dawley rats develop spontaneous C-cell hyperplasia at elevated background rates compared with humans. The FDA's own pharmacology review for liraglutide (the first GLP-1 agonist to receive this warning) concluded that the rat model may not be predictive of human risk due to these receptor and proliferative differences [4].
• Calcitonin data in human trials. Across the SURMOUNT program, mean serum calcitonin levels did not show a clinically meaningful rise in the tirzepatide arms relative to placebo. Calcitonin is the primary biomarker for C-cell proliferation and MTC.

What the FDA Label Actually States

The Zepbound prescribing information states: "It is unknown whether Zepbound causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined" [2]. That language is precise. The FDA is not asserting causation; it is flagging an unresolved question that warrants ongoing surveillance.

SURMOUNT-1: Cancer Adverse Events in the Primary Trial

SURMOUNT-1 was a randomized, double-blind, placebo-controlled trial published in the New England Journal of Medicine in 2022 [1]. It enrolled 2,539 adults with a BMI of 30 or higher (or 27 with at least one weight-related comorbidity) and randomized them to tirzepatide 5 mg, 10 mg, or 15 mg weekly, or placebo, over 72 weeks.

Reported Neoplasms in the Trial

The supplementary safety tables from SURMOUNT-1 reported neoplasms as a combined adverse-event category. The incidence of malignant neoplasms was numerically similar between the tirzepatide arms and placebo, with no statistically significant difference at P<0.05 for any cancer subtype. The trial was not powered to detect rare cancer signals; 72 weeks is also too short a follow-up to capture most solid-tumor endpoints with statistical confidence.

No cases of medullary thyroid carcinoma were reported in SURMOUNT-1, SURMOUNT-2, SURMOUNT-3, or SURMOUNT-4 [1][5].

Limitations of Trial-Based Cancer Surveillance

A 72-week phase 3 trial with roughly 2,500 participants cannot rule out a small absolute increase in cancer risk. MTC has a low baseline incidence of approximately 0.57 cases per 100,000 person-years in the general U.S. Population according to SEER data from the National Cancer Institute. Detecting a doubling of that rate would require tens of thousands of patient-years of follow-up. Post-marketing registries and long-term extension studies are the appropriate tools for that question.

The GLP-1 Class: Broader Epidemiological Evidence

Tirzepatide has been on the market for a shorter period than the older GLP-1 receptor agonists, so the longest-duration human safety data come from liraglutide and semaglutide.

Liraglutide Thyroid Data

Liraglutide received FDA approval in 2010. A 2022 Danish registry study published in JAMA by Pasternak et al. (N=145,410 GLP-1 agonist users matched to non-users) found no statistically significant association between GLP-1 receptor agonist use and MTC over a median follow-up of 3.9 years (adjusted hazard ratio 1.46, 95% CI 0.60 to 3.58) [6]. The confidence interval is wide, which reflects the rarity of MTC rather than evidence of harm.

Semaglutide Thyroid Data

The SUSTAIN and STEP programs for semaglutide, which collectively enrolled more than 20,000 patients, reported no confirmed MTC cases in either the subcutaneous or oral formulations [7]. The FDA's 2021 review of the semaglutide NDA for weight management (Wegovy) concluded that the available human data did not establish a causal relationship between semaglutide and MTC.

Pancreatic Cancer Signal

A separate concern raised in early post-marketing literature for GLP-1 agonists was a potential signal for pancreatic ductal adenocarcinoma. The LEADER trial (N=9,340, median follow-up 3.8 years) and SUSTAIN-6 (N=3,297, 2-year follow-up) found no significant increase in pancreatic cancer rates with liraglutide or semaglutide versus comparators [8]. SURMOUNT-1 reported 4 total pancreatitis cases across all tirzepatide arms (0.3%) versus 0 in placebo, which the FDA label flags as a risk requiring clinical judgment in patients with a history of pancreatitis [2]. Acute pancreatitis and pancreatic cancer are biologically distinct; chronic, recurrent pancreatitis is a recognized risk factor for pancreatic cancer, but a single episode or drug-induced acute pancreatitis does not establish the same trajectory.

Obesity, Cancer, and the Counterbalancing Risk Equation

This section requires a number that is rarely quoted in patient-facing materials: obesity is itself a confirmed risk factor for 13 cancers classified by the International Agency for Research on Cancer (IARC). Those 13 include endometrial, esophageal adenocarcinoma, gastric cardia, liver, kidney, multiple myeloma, meningioma, pancreatic, colorectal, gallbladder, breast (postmenopausal), ovarian, and thyroid (follicular and papillary, not medullary) cancers [9].

Quantifying Obesity-Attributable Cancer Burden

The CDC estimates that overweight and obesity account for approximately 40% of all cancers diagnosed annually in the United States, roughly 630,000 cases per year [10]. A sustained 20% body-weight reduction of the magnitude seen in SURMOUNT-1 could meaningfully reduce the patient's absolute risk for several of those 13 cancer types.

Does Weight Loss with GLP-1 Agonists Reduce Cancer Risk?

No prospective randomized trial has yet used cancer incidence as a primary endpoint for a GLP-1 agonist. Observational data are early. A 2023 retrospective analysis by Wang et al. In JAMA Network Open (N=6,356 patients with obesity and type 2 diabetes, mean follow-up 7.9 years) found that GLP-1 receptor agonist use was associated with a statistically significant reduction in the risk of 10 of 13 obesity-associated cancers compared with insulin, with the strongest signals for gallbladder cancer (HR 0.35, 95% CI 0.15 to 0.83) and meningioma (HR 0.37, 95% CI 0.15 to 0.90) [11]. This was an observational study and cannot establish causation, but the direction of effect is clinically relevant when counseling patients about the overall risk-benefit balance.

The framework below summarizes how clinicians at HealthRX currently weigh the cancer risk signals against each other when a patient with obesity is being considered for tirzepatide:

| Risk Direction | Cancer Type | Signal Strength | Action | |---|---|---|---| | Theoretical increase | Medullary thyroid carcinoma | Preclinical only; no confirmed human cases | Contraindicate in MTC/MEN2 history; baseline calcitonin if clinical suspicion | | No signal established | Pancreatic ductal adenocarcinoma | Acute pancreatitis rare; no causal chain confirmed | Caution with prior pancreatitis history; monitor amylase/lipase if symptoms arise | | Potential decrease | 10 of 13 obesity-associated cancers | Observational; Wang et al. 2023 | Counsel patients on obesity-cancer link; track BMI trajectory | | Under review | Colorectal cancer | Mixed signals in early pharmacoepidemiology | No prescribing change indicated; ongoing registry surveillance |

Contraindications, Screening Recommendations, and Clinical Decision Points

Absolute Contraindications

The Zepbound prescribing information lists the following absolute contraindications related to cancer risk [2]:

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)

These contraindications apply regardless of the absence of confirmed human causation because the theoretical risk cannot be excluded and safer alternatives exist for this population.

Baseline Calcitonin Testing

The label does not mandate routine calcitonin screening for all patients. The Endocrine Society's 2023 clinical practice guideline on thyroid nodules recommends calcitonin measurement "when there is clinical or sonographic suspicion of MTC" rather than as a universal GLP-1 agonist pre-treatment screen [12]. In practice, HealthRX clinicians obtain a baseline calcitonin if the patient reports a family history of thyroid cancer, has an incidentally discovered thyroid nodule, or has unexplained hoarseness or dysphagia.

Monitoring During Treatment

Routine serial calcitonin monitoring in asymptomatic patients is not supported by current guidelines from the American Thyroid Association or the Endocrine Society [12]. Patients should be instructed to report any neck mass, persistent hoarseness, dysphagia, or dyspnea, which are symptoms that warrant thyroid evaluation regardless of drug use.

Pancreatitis Precautions

Before initiating tirzepatide, clinicians should review the patient's history for prior acute pancreatitis, hypertriglyceridemia (a pancreatitis risk factor that tirzepatide can actually improve), gallstone disease, and alcohol use. If a patient develops severe, persistent abdominal pain during treatment, tirzepatide should be discontinued and pancreatitis worked up before considering rechallenge.

Post-Marketing Surveillance: Where the Evidence Stands Now

Tirzepatide received FDA approval for obesity in November 2023. As of early 2025, fewer than 18 months of post-marketing safety data are available for Zepbound specifically. The FDA's MedWatch system collects voluntary adverse event reports; the WHO's VigiBase collects international pharmacovigilance data. Neither database has published an MTC disproportionality analysis specific to tirzepatide as of this writing.

What to Expect from Ongoing Registries

Eli Lilly has committed to a post-marketing MTC registry as a condition of approval, consistent with the commitment made by manufacturers of all GLP-1 receptor agonists. This registry will track calcitonin trends and thyroid cancer diagnoses in tirzepatide-exposed patients over a minimum of 15 years. Meaningful cancer incidence data from that registry will take at least 5 to 10 years to accumulate.

The CVOT (cardiovascular outcomes trial) for tirzepatide, SURPASS-CVOT (NCT04255433), is expected to enroll approximately 14,600 patients with type 2 diabetes and elevated cardiovascular risk over a mean follow-up of about 5 years. Its safety database will provide longer-duration cancer event data than the SURMOUNT program, though it was not powered for cancer endpoints [5].

Interpreting Pharmacovigilance Data Correctly

Spontaneous reporting systems like MedWatch systematically undercount adverse events (estimated 1% to 10% reporting rate for most drug reactions) and cannot establish causation. An elevated reporting odds ratio in VigiBase means only that MTC is being reported more often than expected relative to other drugs in the database, which could reflect channeling bias (physicians ordering calcitonin on GLP-1 agonist patients more often than on controls) rather than a true pharmacological signal.

Communicating Risk to Patients: A Practical Framework

Patients searching "Zepbound cancer risk" are often alarmed by the boxed warning language and may not proceed with treatment that could substantially reduce their cardiometabolic risk burden. A clear, evidence-based explanation should cover three points:

1. The boxed warning originated in animal studies; no confirmed human MTC cases have been causally attributed to tirzepatide or any other GLP-1 agonist to date.
2. Obesity independently raises cancer risk across 13 cancer types, and the magnitude of weight loss achievable with tirzepatide may reduce that background risk.
3. Patients with a personal or family history of MTC or MEN2 should not use this drug, full stop.

The American Association of Clinical Endocrinology (AACE) 2023 consensus statement on obesity pharmacotherapy notes that "the overall benefit-risk profile of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists favors their use in appropriately selected patients with obesity, recognizing that the thyroid C-cell signal has not been confirmed in human populations" [13].